Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, including protein misfolding, cell cycle dysregulation, neurodegeneration and apoptosis (Programmed Cell Death). Degenerative disorders such as Parkinson’s, Alzheimer’s, Retinitis Pigmentosa, Diabetes and ALS as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain small molecules, biologics, and biomarkers surrounding the intellectual property and proprietary technologies it owns and to which it has licenses to treat and/or diagnose Parkinson’s disease, Alzheimer’s disease, Retinitis Pigmentosa and other human diseases. SNNLive spoke with Gerald Commissiong, President and CEO of Amarantus BioScience Holdings, Inc. at the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Commissiong begins with an overview of the company, “Amarantus is a biotech company focused on developing products through critical stage development and then driving value from them. We’ve got a blood test for Alzheimer’s disease that we’re going to be launching this year in the next few weeks for the investigational use only for the pharmaceutical industry and in 2015 we’ll be launching it for the broad commercial market, we have a phase 2b program for Parkinson’s disease, Dyskinesia’s that will be starting in early 2015 expected to read out in 2016, that same program is moving to an end to phase 2 meeting in adult ADHD. We have a preclinical program for blindness due to retinitis pigmentosa that is in front of the FDA now with an orphan drug designation application that expected to read out very shortly and we recently announced that we’re in the process of acquiring a product for treatment of severe burns with over 150 patients of human data that is expected to become the new standard of care in a very short period of time.”
He concludes by discusses growth in 2015, “2015 is going to be a period of extreme growth for the company and 2013, we stabilized the company and gained financing, in 2014 we added to our product portfolio, we’ve development LymPro to the stage now where it’s ready to be commercialized. 2015 we expected to derive value from that commercialization through spinning off the asset, we’re going to be starting the phase IIB program that we recently acquired, we’re going to complete the acquisition of the burn product phase IIA and we expect that we’ll soon be ready to in 2015, early 2016 start first man studies for Retinitis Pigmentosa.” For more information, check out their website: www.Amarantus.com
© 2017 Stock News Now
Supported by Superior Web Solutions